William Hodder Email & Phone Number

California, United States

Boston, Ma, Us

San Diego, Ca, Us

Assist private (pre-funded and funded) and public biotech companies with various fundraising, corporate development, licensing and marketing activities.

Houston, Texas, Us

Newark, California, Us

Corporate Officer managing Corporate Development for a peptide therapeutics company focused on gastrointestinal diseases utilizing a proprietary platform technology. Responsible for licensing, M&A, and other significant contracting activities including real estate. Completed the out-licensing of a pre-clinical oral peptide program, PTG-200, to Janssen in May 2017. Financial terms included $990M in total milestones including $50M upfront and $325M in near-term milestones through the completion of Phase 2. Significant contributor to the completion of an upsized $90M IPO in August 2016 and a $40M Series C round in July 2015 which included new venture capital and cross-over investors. Also responsible for other corporate operations and administrative functions, including developing and implementing infrastructure to support the growth of the organization.

Assist private (pre-funded and funded) and public biotech companies with various fundraising, corporate development, licensing and marketing activities.

Founded company to seek funding for the development of LDN-193189, a small molecule BMP/ALK receptor kinase inhibitor discovered at Massachusetts General/Brigham and Women’s Hospital and the discovery of 2nd generation ALK inhibitors.

San Francisco, Ca, Us

Corporate officer and member of the executive management team. Responsible for all licensing and M&A activity and ongoing partner Alliance Management. Managed a team of 4 – 6 professionals.Significant activities included:• Out-licensing of HIF prolyl hydroxylase inhibitors for anemia indications to Yamanouchi for the Japan territory in April 2004. Deal terms included $18.5M cash upfront, $30.5M equity investment and significant development and sales milestones.• Out-licensing of HIF prolyl hydroxylase inhibitors for anemia indications to Astellas for the European, South Africa and Middle East territories in February 2006. Deal terms included $300M cash upfront, $50M equity investment and significant development and sales milestones. Transaction voted most significant partnering deal of 2006 at The Biotech Meeting at Laguna Niguel.• Completed transactions to secure cell lines and manufacturing capacity for FibroGen’s monoclonal antibody program.• In-licensed or acquired additional intellectual property from various academic institutions and companies to support the therapeutic and biomaterial programs at FibroGen. Acquired an academic spinoff company to support the HIF prolyl hydroxylase program.• Executed feasibility and commercial development agreements for the biomaterials program with leading biotech, pharmaceutical, medical device and drug delivery companies.• Responsible for the completion of the Private Placement Memorandum and led a selling team focused on hedge funds and mutual funds in the completion of a Series F round of fundraising which raised $120M. Transaction voted most significant fundraising of 2004 at The Biotech Meeting at Laguna Niguel.

Negotiated and executed feasibility agreements with biotech and pharmaceutical companies for pulmonary drug delivery technology. Developed and implemented yearly strategic business development and marketing plans. Directed advertising and public relations activities to support corporate development goals. Directed deal negotiation and due diligence process including legal review of contracts. Managed ongoing relationships with feasibility and commercial partners providing commercial and strategic input.

Responsible for the pre-launch and launch marketing activities for AVITA, a prescription acne product. Activities included the development and execution of clinical study publication strategy, development of speakers’ bureau, and the selection and direction of advertising agency. Directed various marketing research activities leading to the formulation of product positioning, product brand name and pricing strategy. Developed prescription and sales forecasting models. Leader of Project Team responsible for gaining FDA approval and ensuring product availability for launch. Provided strategic input regarding clinical study design for other products in Penederm’s portfolio. Analyzed potential business development opportunities and formulated recommendations for senior management. Penederm is now part of Mylan Pharmaceuticals.

Responsible for managing advertising agency through the creation of marketing materials for personal and non-personal promotion. Developed yearly marketing plans including family positioning strategy for all anti-inflammatory products in Ciba’s portfolio. Directed market research for positioning and concept testing of future line extensions of VOLTAREN, Ciba’s largest product. Developed monthly production and sampling forecasts with marketing research and manufacturing personnel. Worked with team to complete positioning and launch strategy, including marketing materials for CATAFLAM. Led project team to design and execute Phase IV clinical trials for CATAFLAM. Ciba-Geigy is now part of Novartis.

Performed competitor analysis of current and future products in prescription analgesia market. Initiatedand developed physician focus groups to identify physicians’ perceptions and use of prescriptionanalgesics. Analyzed market issues to determine positioning of new prescription analgesic. Investigated product concepts for launch strategy and presented analysis and recommendations to management.

Lawrence Township, Nj, Us

Promoted prescription and over-the-counter products to doctors, pharmacies, hospitals and wholesalers. Metropolitan Detroit sales territory.

Promoted prescription and over-the-counter products to doctors, pharmacies, hospitals and wholesalers. Pontiac, Michigan sales territory. Marion Labs is now part of Sanofi.

Master Of Business Administration

Bachelor Of Science, Biology